• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal".

作者信息

Daly Adrian F

机构信息

Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, Liège, Belgium.

出版信息

J Clin Pharm Ther. 2022 Sep;47(9):1490. doi: 10.1111/jcpt.13651. Epub 2022 Mar 21.

DOI:10.1111/jcpt.13651
PMID:35313386
Abstract
摘要

相似文献

1
Comment on "Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal".关于“生长激素分泌型垂体腺瘤患者肢端肥大症的持续缓解：长效帕瑞肽治疗效果及停药后果”的评论
J Clin Pharm Ther. 2022 Sep;47(9):1490. doi: 10.1111/jcpt.13651. Epub 2022 Mar 21.
2
Persistent remission of acromegaly in a patient with GH-secreting pituitary adenoma: Effect of treatment with pasireotide long-acting release and consequence of treatment withdrawal.生长激素分泌型垂体腺瘤患者的肢端肥大症持续缓解：帕瑞肽长效释放制剂治疗的效果及停药后果。
J Clin Pharm Ther. 2022 Jun;47(6):835-840. doi: 10.1111/jcpt.13615. Epub 2022 Feb 15.
3
Pasireotide versus octreotide in acromegaly: a head-to-head superiority study.培高利特与奥曲肽治疗肢端肥大症的头对头优效性研究。
J Clin Endocrinol Metab. 2014 Mar;99(3):791-9. doi: 10.1210/jc.2013-2480. Epub 2014 Jan 13.
4
Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.帕瑞肽对肢端肥大症垂体肿瘤的潜在抗肿瘤活性。
Lancet Diabetes Endocrinol. 2019 Jun;7(6):425-426. doi: 10.1016/S2213-8587(19)30113-5. Epub 2019 Apr 4.
5
Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.长效帕瑞肽治疗生长抑素受体不敏感型肢端肥大症的疗效和安全性：一项多中心研究。
Endocrine. 2018 Nov;62(2):448-455. doi: 10.1007/s12020-018-1690-5. Epub 2018 Jul 26.
6
Cardiometabolic Risk in Acromegaly: A Review With a Focus on Pasireotide.肢端肥大症的心脏代谢风险：帕瑞肽为重点的综述
Front Endocrinol (Lausanne). 2020 Feb 6;11:28. doi: 10.3389/fendo.2020.00028. eCollection 2020.
7
Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study.帕西瑞肽长效注射剂在肢端肥大症患者中维持对生长激素（GH）和胰岛素样生长因子-1（IGF-1）的抑制作用长达25个月：一项随机、双盲、多中心III期研究的盲法延长期结果
Pituitary. 2015 Jun;18(3):385-94. doi: 10.1007/s11102-014-0585-6.
8
Medical treatment of acromegaly - When the tumor size matters: A narrative review.肢端肥大症的治疗——当肿瘤大小起作用时：一篇叙述性综述。
Growth Horm IGF Res. 2024 Oct;78:101608. doi: 10.1016/j.ghir.2024.101608. Epub 2024 Aug 2.
9
The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.生长抑素类似物疗法对肢端肥大症患者垂体瘤体积的影响。
Pituitary. 2016 Apr;19(2):210-21. doi: 10.1007/s11102-015-0677-y.
10
Discontinuation of somatostatin analogs while acromegaly is in long-term remission.在肢端肥大症处于长期缓解期时停用生长抑素类似物。
Pituitary. 2015 Aug;18(4):554-60. doi: 10.1007/s11102-014-0608-3.

引用本文的文献

1
Long-term Remission in Functioning Pituitary Adenomas after Medical Therapy Withdrawal: A Chance for Cushing's Disease.药物治疗停药后功能性垂体腺瘤的长期缓解：库欣病的一个机会。
Endocr Metab Immune Disord Drug Targets. 2025;25(10):824-833. doi: 10.2174/0118715303328077240719055819.